Our most recent publication looks at global immunisation funding, and highlights that despite the societal and economic value of immunisation programmes, expenditure remains disproportionately low. The report calls for governments to reassess national immunisation spending, review approaches to increase and protect prevention funding, enhance programme delivery, and improve data collection and reporting.
The growing recognition that healthcare interventions may perform differently in real-world settings compared to clinical trials has raised the importance of Real-World Evidence (RWE). RWE can be informative for decision-makers for determining cost-effectiveness and value in healthcare financing. One of our reports in this Bulletin focuses on best practices for the generation and use of RWE, and looks at key considerations for its use to assess clinical and comparative effectiveness to inform HTA reimbursement decisions.
Alongside these broader approaches to evidence and funding, a recent blog discusses insights from new research to develop a “cognition bolt-on” for the EQ-5D-5L instrument. The research explores how best to measure cognition, which is increasingly recognised as central to health-related quality of life. By improving how we measure health outcomes, we can better inform resource allocation decisions, in particular where determining cost-effectiveness is challenging due to subtle health status changes.
